Category - Developments

Developments

Zynerba Pharmaceuticals initiates Phase 2 trial of CBD gel for autism spectrum disorder

Zynerba Pharmaceuticals (NASDAQ:ZYNE) initiated a Phase 2 trial to assess the safety, tolerability and efficacy of Zygel for the treatment of autism spectrum disorder (ASD). Zygel in a cannabidiol-based gel that...

March 11, 2019

Developments

Seelos Therapeutics acquires exclusive license to Parkinson’s disease therapy

Seelos Therapeutics (NASDAQ:SEEL) acquired an exclusive license to a family of peptide inhibitors that target the aggregation of alpha-synuclein, a protein implicated in Parkinson’s disease (PD). Seelos will develop the...

March 8, 2019

Developments

Tonix Pharmaceuticals receives new European use patent for PTSD drug

Tonix Pharmaceuticals (NASDAQ:TNXP) received a new European use patent for TNX-601, providing intellectual property protection until 2029 for the treatment of neurocognitive dysfunction associated with corticosteroids...

March 8, 2019

Developments

Stellar Biotech, Edesa Biotech to merge in stock swap

Stellar Biotechnologies (NASDAQ:SBOT) has executed a share exchange agreement with closely-held Edesa Biotech to create a new company focused on the development of innovative therapeutics for dermatological and...

March 8, 2019

Developments

“London patient” is second to experience sustained HIV remission following stem cell transplant

A UK man who received a stem cell transplant from a donor with the rare CCR5-delta 32 mutation is believed to effectively be cured from HIV. The CCR5-delta 32 genetic mutation hampers HIV’s ability to enter host cells...

March 6, 2019

Developments

BeyondSpring presents promising CIN data at ASCO-SITC clinical immuno-oncology symposium

BeyondSpring (NASDAQ:BYSI) presented new clinical results from its Study 106 program in the prevention of chemotherapy-induced neutropenia (CIN) for its lead asset Plinabulin at the 2019 ASCO-SITC clinical immuno...

March 5, 2019

Developments

Titan Pharmaceuticals implant for opioid use disorder attracts media attention in Canada

An implant developed by Titan Pharmaceuticals (NASDAQ:TTNP) for the treatment of opioid use disorder (OUD) is drawing attention in Canada. Marketed under the brand name Probuphine, the first-of-its-kind implant delivers...

March 4, 2019

Developments

Genetic meta-analysis identifies four new genetic variants associated with Alzheimer’s disease

A genome-wide association study of 94,000 individuals has identified four new genetic variants that play a role in the development of late-onset Alzheimer’s disease (AD). Conducted by an international consortium of...

March 1, 2019

Developments

Novavax Phase 3 ResVax trial misses primary endpoint

Novavax (NASDAQ:NVAX) reported that its Phase 3 PREPARE studyfor ResVax, a RSV (respiratory syncytial virus) F vaccine, did not meet its primary objective of preventing medically significant RSV lower respiratory tract...

March 1, 2019

Developments

Guardant Health liquid biopsy beats tissue testing in advanced non-small cell lung cancer

In a prospective multi-center study of 282 newly diagnosed non-small cell lung cancer patients, Guardant Health’s (NASDAQ:GH) liquid biopsy genomic assay, Guardant360, outperformed standard-of-care tissue testing in...

March 1, 2019

Category - Developments

Zynerba Pharmaceuticals initiates Phase 2 trial of CBD gel for autism spectrum disorder

Seelos Therapeutics acquires exclusive license to Parkinson’s disease therapy

Tonix Pharmaceuticals receives new European use patent for PTSD drug

Stellar Biotech, Edesa Biotech to merge in stock swap

“London patient” is second to experience sustained HIV remission following stem cell transplant

BeyondSpring presents promising CIN data at ASCO-SITC clinical immuno-oncology symposium

Titan Pharmaceuticals implant for opioid use disorder attracts media attention in Canada

Genetic meta-analysis identifies four new genetic variants associated with Alzheimer’s disease

Novavax Phase 3 ResVax trial misses primary endpoint

Guardant Health liquid biopsy beats tissue testing in advanced non-small cell lung cancer

General

More